Clinical trials
Phase 1 Retinal Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Active, not recruiting | 3 |
| Recruiting | 3 |
| Terminated | 3 |
| Unknown status | 3 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| InnoVec Biotherapeutics Inc. | 2 |
| National Eye Institute (NEI) | 2 |
| The New York Eye Cancer Center | 2 |
| Adverum Biotechnologies, Inc. | 1 |
| Beijing Tongren Hospital | 1 |
| Cedars-Sinai Medical Center | 1 |
| David M. Brown, M.D. | 1 |
| Gemini Therapeutics, Inc. | 1 |
| GlaxoSmithKline | 1 |
| King Khaled Eye Specialist Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Retinal Diseases | 30 |
| Macular Degeneration | 8 |
| Eye Diseases | 7 |
| Retinal Degeneration | 6 |
| Diabetic Retinopathy | 5 |
| Macular Edema | 5 |
| Retinal Vein Occlusion | 4 |
| Retinitis Pigmentosa | 3 |
| Diabetes Mellitus | 2 |
| Neovascularization, Pathologic | 2 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.